Corporate Profile

We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Akero Therapeutics – developing efruxifermin (EFX) for NASH>

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

More events are coming soon.